Literature DB >> 22231457

Influence of pregnancy on the adipocytokine and peroxisome proliferator-activated receptor pathways in peripheral blood mononuclear cells from healthy donors and rheumatoid arthritis patients.

Janine Weix1, Frauke Förger, Thomas Häupl, Daniel Surbek, Monika Østensen, Peter M Villiger.   

Abstract

OBJECTIVE: To identify candidate genes that are regulated by human pregnancy and have the potential to modulate rheumatoid arthritis (RA) disease activity.
METHODS: Peripheral blood mononuclear cells (PBMCs) from healthy pregnant volunteers were analyzed using Affymetrix GeneChips at 4 time points (during the first, second, and third trimesters and 6 weeks postpartum). Based on the GeneChip data, target genes were further analyzed via real-time quantitative polymerase chain reaction (qPCR) using PBMCs from healthy controls and RA patients. In order to determine the cellular source of the candidate gene messenger RNA (mRNA), monocytes and lymphocytes from healthy controls and RA patients were positively selected using magnetic beads, and their mRNA was analyzed by qPCR.
RESULTS: One-way analysis of variance identified 1,286 mRNAs that were differentially expressed with regard to the 4 time points. The changes became more pronounced as pregnancy progressed, and they were reversed postpartum. A subsequent pathway analysis suggested a regulatory role of pregnancy on the adipocytokine pathway as well as on the peroxisome proliferator-activated receptor (PPAR) signaling pathway. Of 19 preselected candidate genes, AKT3, SOCS3, FADS2, STAT1, and CD36 proved to be differentially regulated by pregnancy. In samples from RA patients, the differences were concordant with those in healthy controls but more pronounced. Both T lymphocytes and monocytes contributed to the regulated expression of these genes.
CONCLUSION: Our findings indicate that normal human pregnancy leads to changes in the expression of several molecular pathways in PBMCs, which are reversed postpartum. Changes in RA patients, although concordant, exceed the levels observed in healthy controls. Genes of the adipocytokine and PPAR signaling pathways qualify as candidates for the modulation of RA disease activity during pregnancy.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231457     DOI: 10.1002/art.34375

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  Inhibition of peroxisome proliferator-activated receptor γ: a potential link between chronic maternal hypoxia and impaired fetal growth.

Authors:  Colleen G Julian; Ivana V Yang; Vaughn A Browne; Enrique Vargas; Carmelo Rodriguez; Brent S Pedersen; Lorna G Moore; David A Schwartz
Journal:  FASEB J       Date:  2013-12-04       Impact factor: 5.191

2.  Pregnancy-Induced Changes in Systemic Gene Expression among Healthy Women and Women with Rheumatoid Arthritis.

Authors:  Anuradha Mittal; Lior Pachter; J Lee Nelson; Hanne Kjærgaard; Mette Kiel Smed; Virginia L Gildengorin; Vibeke Zoffmann; Merete Lund Hetland; Nicholas P Jewell; Jørn Olsen; Damini Jawaheer
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

3.  Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study.

Authors:  Dana E Goin; Mette Kiel Smed; Lior Pachter; Elizabeth Purdom; J Lee Nelson; Hanne Kjærgaard; Jørn Olsen; Merete Lund Hetland; Vibeke Zoffmann; Bent Ottesen; Damini Jawaheer
Journal:  Arthritis Res Ther       Date:  2017-05-25       Impact factor: 5.156

4.  Shikonin Inhibits Inflammatory Response in Rheumatoid Arthritis Synovial Fibroblasts via lncRNA-NR024118.

Authors:  Ke-Ya Yang; Dong-Liang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-10       Impact factor: 2.629

5.  Characterization of gene expression changes over healthy term pregnancies.

Authors:  Anna K Knight; Anne L Dunlop; Varun Kilaru; Dawayland Cobb; Elizabeth J Corwin; Karen N Conneely; Alicia K Smith
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.